European Journal of Clinical Pharmacology

, Volume 31, Issue 4, pp 443–448 | Cite as

Treatment of hydatid disease with high oral doses of mebendazole

Long-term follow-up of plasma mebendazole levels and drug interactions
  • P. J. Luder
  • B. Siffert
  • F. Witassek
  • F. Meister
  • J. Bircher


Plasma mebendazole levels were analysed retrospectively in patients treated for inoperable infections withEchinococcus multilocularis orgranulosus. In 10 patients receiving mebendazole at 4 dose levels there was no relation between dose and plasma concentration. In 17 patients followed on the same dose for more than 18 months, the plasma levels varied with individual coefficients of variation ranging from 27 to 72%. The data reveal the limitations of single measurements of plasma mebendazole and emphasize the need for repeated monitoring. Coadministration of phenytoin and carbamazepine seemed to lower plasma levels, presumably as a result of enzyme induction. It was not possible appreciably to raise the mebendazole concentrations by inhibition of drug metabolizing enzymes with cimetidine.

Key words

echinococcosis mebendazole long-term course plasma levels drug interactions cimetidine ursodeoxycholic acid 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Braithwaite PA, Roberts MS, Allan RJ, Watson TR (1982) Clinical pharmacokinetics of high dose mebendazole in patients treated for crystic hydatid disease. Eur J Clin Pharmacol 22: 161–169Google Scholar
  2. 2.
    Bryceson ADM, Cowie AGA, Macleod C, White S, Edwards D, Smyth JD, McManus DP (1982) Experience with mebendazole in the treatment of inoperable hydatid disease in England. Trans Roy Soc Med Hyg 76: 510–518Google Scholar
  3. 3.
    Dawson M, Allan RJ, Watson TR (1982) The pharmacokinetics and bioavailability of mebendazole in man: A pilot study using 3H-mebendazole. Br J Clin Pharmacol 14: 453–455Google Scholar
  4. 4.
    Feely J, Wilkinson GR, Wood AJ (1981) Reduction of liver blood flow and propranolol metabolism by cimetidine. N Engl J Med 304: 692–695Google Scholar
  5. 5.
    Kaojarern S, Feldman M, Richardson CT, Brater DC (1981) Tiotidine and cimetidine — kinetics and dynamics. Clin Pharmacol Ther 29: 198–202Google Scholar
  6. 6.
    Karlaganis G, Münst GJ, Bircher J (1979) High pressure liquid chromatographic determination of the anthelmintic drug mebendazole in plasma. HRC & CC 2: 141–144Google Scholar
  7. 7.
    Knodell RG, Holtzman JL, Crankshaw DL, Steele NM (1982) Drug metabolism by rat and human hepatic microsomes in response to interaction with H2-receptor antagonists. Gastroenterology 82: 84–88Google Scholar
  8. 8.
    Luder PJ, Robotti G, Meister FP, Bircher J (1985) High oral doses of mebendazole interfere with growth of larvalEchinococcus multilocularis lesions. J Hepatol 1: 369–377Google Scholar
  9. 9.
    Luder PJ, Witassek F, Weigand K, Eckert J, Bircher J (1985) Treatment of cystic ehinococcosis(Echinococcus granulosus) with mebendazole: assessment of bound and free drug levels in cyst fluid and of parasite vitality in operative specimens. Eur J Clin Pharmacol 28: 279–285Google Scholar
  10. 10.
    Michiels M, Hendriks R, Heykants J (1978) A sensitive radio-immuno-assay for mebendazole (R 17635) and flubendazole (R 17889). Janssen research products information service. Preclinical Research Reports Nos R 17635/11 and R 17889/9Google Scholar
  11. 11.
    Müller E, Akovbiantz A, Ammann RW, Bircher J, Eckert J, Wissler K, Witassek F, Wüthrich B (1982) Treatment of human echinococcosis with mebendazole. Preliminary observations in 28 patients. Hepatogastroenterology 29: 236–239Google Scholar
  12. 12.
    Münst GJ, Karlaganis G, Bircher J (1980) Plasma concentrations of mebendazole during treatment of echinococcosis. Preliminary results. Eur J Clin Pharmacol 17: 375–378Google Scholar
  13. 13.
    Park BK, Breckenridge AM (1981) Clinical implications of enzyme induction and enzyme inhibition. Clin Pharmacokinet 6: 1–24Google Scholar
  14. 14.
    Perucca E (1982) Pharmacokinetic interactions with antiepileptic drugs. Clin Pharmacokinet 7: 57–84Google Scholar
  15. 15.
    Somogyi A, Gugler R (1982) Drug interactions with cimetidine. Clin Pharmacokinet 7: 23–41Google Scholar
  16. 16.
    Sonne J, Poulsen HE, Døssing M, Larsen NE, Andreasen PB (1981) Cimetidine clearance and bioavailability in hepatic cirrhosis. Clin Pharmacol Ther 29: 191–197Google Scholar
  17. 17.
    Speeg KV, Patwardhan RV, Avant GR, Mitchell MC, Schenker S (1982) Inhibition of microsomal drug metabolism by histamine H2-receptor antagonists studied in vivo and in vitro in rodents. Gastroenterology 82: 89–96Google Scholar
  18. 18.
    WHO Guidelines for surveillance, prevention and control of echinococcosis/hydatidosis (1984) Eckert J, Gemmell MA, Mathyas Z, Soulsby EJL (eds), VPH/81.28Google Scholar
  19. 19.
    Witassek F, Burkhardt B, Eckert J, Bircher J (1981) Chemotherapy of alveolar echinococcosis. Comparison of plasma mebendazole concentrations in animals and man. Eur J Clin Pharmacol 20: 427–433Google Scholar
  20. 20.
    Witassek F, Allan RJ, Watson TR, Woodtli W, Ammann R, Bircher J (1983) Preliminary observations on the biliary elimination of mebendazole and its metabolites in patients with echinococcosis. Eur J Clin Pharmacol 25: 81–84Google Scholar
  21. 21.
    Witassek F, Bircher J (1983) Chemotherapy of larval echinococcosis with mebendazole: Microsomal liver function and cholestasis as determinants of plasma drug level. Eur J Clin Pharmacol 25: 85–90Google Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • P. J. Luder
    • 1
  • B. Siffert
    • 1
  • F. Witassek
    • 1
  • F. Meister
    • 1
  • J. Bircher
    • 1
    • 2
  1. 1.Department of Clinical PharmacologyUniversity of BerneBerneSwitzerland
  2. 2.Department of Clinical PharmacologyUniversity of GöttingenGöttingenGermany

Personalised recommendations